Literature DB >> 2583866

Monoclonal antibody against human squamous-cell-carcinoma-associated antigen.

R J Tatake1, K M Amin, H S Maniar, N A Jambhekar, S S Srikhande, S G Gangal.   

Abstract

Mouse monoclonal antibody (MAb) 3F8E3 (IgG3k) was developed against the head and neck cancer cell line LICR-LON-HN2. Subjected to indirect immunofluorescence, the MAb reacted exclusively with SCC cell lines and showed no reactivity with normal or transformed mouse and human non-SCC cell lines and hematopoietic cell lines. The radiolabelled MAb showed an affinity constant of 1.8 x 10(8) M-1 with HN2 cells and identified 2.07 x 10(4) sites/cell by Scatchard analysis. It identified 2 peptides from membrane extracts of HN2 cells by Western blotting. Avidin-biotin-complexed immunoperoxidase staining on cryostat sections of tumors from various tissues revealed that 3F8E3 reacted mainly with the membrane antigens of well differentiated SCC cells of oral cavity, larynx, esophagus, lung, uterine cervix, metastatic nodes of patients with oral cancer, and dysplastic cells in oral leukoplakia. The MAb did not react with poorly differentiated cells of Ca esophagus, adenocarcinoma of breast, stomach and colon, renal-cell carcinoma and soft-tissue sarcoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583866     DOI: 10.1002/ijc.2910440516

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Establishment and characterization of four new squamous cell carcinoma cell lines derived from oral tumors.

Authors:  R J Tatake; N Rajaram; R N Damle; B Balsara; A N Bhisey; S G Gangal
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.

Authors:  M Gerretsen; J J Quak; J S Suh; M van Walsum; C J Meijer; G B Snow; G A van Dongen
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.